ES2170807T3 - Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria. - Google Patents

Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.

Info

Publication number
ES2170807T3
ES2170807T3 ES95932999T ES95932999T ES2170807T3 ES 2170807 T3 ES2170807 T3 ES 2170807T3 ES 95932999 T ES95932999 T ES 95932999T ES 95932999 T ES95932999 T ES 95932999T ES 2170807 T3 ES2170807 T3 ES 2170807T3
Authority
ES
Spain
Prior art keywords
prostaglandin
prevention
treatment
pct
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932999T
Other languages
English (en)
Inventor
Johan Stjernschantz
Bahram Resul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synphora AB
Original Assignee
Synphora AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synphora AB filed Critical Synphora AB
Application granted granted Critical
Publication of ES2170807T3 publication Critical patent/ES2170807T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)

Abstract

METODO PARA TRATAR O PREVENIR LAS CATARATAS SECUNDARIAS QUE SUPONE LA PUESTA EN CONTACTO DE LA SUPERFICIE DEL OJO CON UNA CANTIDAD EFECTIVA DE UNA PROSTAGLANDINA TERAPEUTICAMENTE ACTIVA Y ACEPTABLE FISIOLOGICAMENTE DEL TIPO A O J, ESPECIALMENTE PGA{SUB,2} O PGJ{SUB,2} O UN ANALOGO O DERIVADO DE LO ANTERIOR.
ES95932999T 1994-09-21 1995-09-19 Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria. Expired - Lifetime ES2170807T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403160A SE9403160D0 (sv) 1994-09-21 1994-09-21 Method and means for prevention and treatment of secondary cataract

Publications (1)

Publication Number Publication Date
ES2170807T3 true ES2170807T3 (es) 2002-08-16

Family

ID=20395311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932999T Expired - Lifetime ES2170807T3 (es) 1994-09-21 1995-09-19 Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.

Country Status (10)

Country Link
US (1) US5760075A (es)
EP (1) EP0782447B1 (es)
JP (1) JPH10505860A (es)
AT (1) ATE213634T1 (es)
AU (1) AU704459B2 (es)
CA (1) CA2200481C (es)
DE (1) DE69525631T2 (es)
ES (1) ES2170807T3 (es)
SE (1) SE9403160D0 (es)
WO (1) WO1996009054A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
WO1999005278A1 (en) * 1997-07-23 1999-02-04 Brigham & Women's Hospital, Inc. Lens epithelial cell derived growth factor
US6533769B2 (en) * 2001-05-03 2003-03-18 Holmen Joergen Method for use in cataract surgery
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
CN101060831B (zh) * 2004-10-01 2010-06-23 拉姆斯科股份有限公司 可方便植入的缓释药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
JPH0643313B2 (ja) * 1986-03-13 1994-06-08 ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク 緑内障の局所治療用組成物
TW249226B (es) * 1990-04-04 1995-06-11 Aderk Ueno Kk

Also Published As

Publication number Publication date
EP0782447A1 (en) 1997-07-09
SE9403160D0 (sv) 1994-09-21
ATE213634T1 (de) 2002-03-15
AU3581695A (en) 1996-04-09
EP0782447B1 (en) 2002-02-27
DE69525631D1 (de) 2002-04-04
JPH10505860A (ja) 1998-06-09
CA2200481C (en) 2002-09-10
WO1996009054A1 (en) 1996-03-28
US5760075A (en) 1998-06-02
DE69525631T2 (de) 2002-07-18
AU704459B2 (en) 1999-04-22
CA2200481A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
AU3402295A (en) Methods and means for drug administration
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
MX9307883A (es) Aplicacion del riluzol en la preparcion de un medicamento para el tratamiento de lesiones neurologicas.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
EA200300560A1 (ru) Улучшенный способ лечения
DE69431601D1 (de) Neue verwendung von dexmedetomidin
EP1110554A4 (en) MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
DE68918099D1 (de) Pharmazeutische behandlung einer augenentwicklung.
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
BR9509975A (pt) Formulação farmacêutica
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ES2170807T3 (es) Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
SI0817786T1 (en) Substituted tetronic acids useful for treating hiv and other retroviruses

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 782447

Country of ref document: ES